Mazdutide is a once-weekly injectable peptide that activates two receptors at once: the GLP-1 receptor and the glucagon receptor. The honest bottom line on evidence and status is that phase 3 data exist and a national regulator has approved it, but that regulator is China's National Medical Products Administration, and the compound remains unapproved in the United States and Europe. The two-receptor design is the whole point of the molecule, since the GLP-1 arm lowers energy intake while the glucagon arm is associated with raising energy output.
Mazdutide is a lipidated oxyntomodulin analogue that engages both the GLP-1 and glucagon receptors to cut energy intake while raising energy expenditure, and it is approved in China for chronic weight management and type 2 diabetes while remaining unapproved in the United States and Europe.
The starting point was not a laboratory invention but a hormone the gut already makes. Oxyntomodulin is a 37 amino acid peptide released from intestinal L-cells after eating, cut from the same proglucagon gene that yields GLP-1 and glucagon, and it is unusual in binding both receptors with modest potency at each. Native oxyntomodulin is useless as a drug because dipeptidyl peptidase-4 cleaves it and the kidney clears it within minutes, so the documented engineering work was aimed squarely at durability.
Lipidation and DPP-4-resistant substitutions extend the half-life of a native gut hormone from minutes to days, which is what converts oxyntomodulin from a physiological curiosity into a once-weekly injectable.
A single-receptor GLP-1 agonist works almost entirely on the intake side of the energy equation, and body weight falls because the person eats less. Adding glucagon receptor activity is documented as opening a second lever on the output side, where hepatic and adipose signaling is associated with higher resting energy expenditure and greater lipolysis. That is a different bet from the GLP-1 plus GIP pairing used by tirzepatide, where the second receptor reinforces insulin secretion instead of raising expenditure.
| Design criterion | GLP-1 alone | GLP-1 plus glucagon | GLP-1 plus GIP |
|---|---|---|---|
| Primary lever | Reduced energy intake | Intake plus energy expenditure | Intake plus insulin sensitivity |
| Liver fat effect | Largely downstream of weight loss | Direct hepatic fatty acid oxidation | Largely downstream of weight loss |
| Glycemic risk from second arm | None | Hepatic glucose output, offset by GLP-1 | None |
| Reported class cautions | GI events | GI events, heart rate, transaminase rises | GI events |
The ratio of GLP-1 to glucagon receptor potency is treated in the published design rationale as the central engineering decision, because excess glucagon activity risks hyperglycemia and raised heart rate while too little forfeits the expenditure benefit.
The sequence after a subcutaneous dose is well characterized at the receptor level, and it explains why appetite suppression and nausea are not separate phenomena but two outputs of the same circuitry. One feature carries real clinical weight: the insulin effect is glucose-dependent, which is why incretin-based agents carry a low intrinsic risk of hypoglycemia when used without insulin or a sulfonylurea.
Appetite effects are reported within the first days to weeks of dosing, whereas changes in hepatic fat, glycated hemoglobin, and body composition accumulate over months.
Glucagon's reputation as the fasting hormone that tells the liver to release glucose describes only part of its portfolio. Through the hepatic glucagon receptor and cyclic AMP signaling, it also drives fatty acid oxidation and increases the metabolic cost of hepatic substrate cycling, and human infusion studies with native glucagon demonstrated the resulting rise in resting energy expenditure. That finding is the original argument for building glucagon activity into a weight-management molecule rather than treating it as a liability to be avoided.
Weight loss normally lowers resting energy expenditure, so preserving or raising it during active weight reduction, measured by indirect calorimetry or doubly labeled water, is the meaningful signal rather than the absolute number.
Weekly dosing is not a convenience decision layered onto the molecule; it falls directly out of two engineering choices working together. The depot slows absorption so peak plasma concentrations arrive over roughly a day or more, and albumin binding then holds the great majority of the drug in a slow-release reservoir where only the small unbound fraction is active or available for elimination.
The absence of cytochrome-mediated metabolism limits classical drug-drug interaction concerns, though slowed gastric emptying can still alter the absorption of co-administered oral medications.
Development has run through phase 1 studies in both Western and Chinese populations and into phase 3 programs conducted primarily in China, covering chronic weight management, type 2 diabetes, and exploratory work in metabolic liver disease. The weight-management trials used the field's conventional endpoint pair: percentage change in body weight from baseline, and the proportion of participants reaching at least five percent or at least ten percent reduction. What the record supports and what it does not support diverge sharply once the endpoints move past metabolic surrogates.
Cross-trial comparison against other incretin agents is unreliable because populations, baseline weights, and trial designs differ, and a trial average conceals wide individual variation in response.
Almost every prominent adverse effect is a predictable extension of the mechanism rather than an unrelated toxicity. Gastrointestinal events arise from the same slowed gastric emptying and hindbrain receptor activation that produce satiety, which is why the benefit and the burden of this drug class travel together and why titration, not symptom treatment, is the primary management strategy in the published guidance.
Delayed gastric emptying affects stomach contents during anesthesia, so procedural sedation in patients using this drug class requires advance disclosure of use.
Regulatory standing is jurisdiction-specific, and it is the single most important practical fact about this molecule. The compound originated at Eli Lilly and has been developed for the Chinese market by Innovent Biologics under license, and approval by one national regulator did not carry over to others.
Mazdutide is approved only in China as of this writing, and in any country where it is unapproved the appropriate path documented by clinical guidance is a discussion of approved alternatives with a qualified clinician rather than acquisition of the molecule itself.
Educational use only. This article describes what the published scientific and clinical literature reports about Mazdutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
